Circulating tumor cells can be detected from the peripheral blood of cancer patients. Their prognostic value has been established in the last 10 years for metastatic colorectal, breast, and prostate cancer. On the contrary, their presence in patients affected by sarcomas has been poorly investigated. The discovery of EpCAM mRNA expression in different sarcoma cell lines and in a small cohort of metastatic sarcoma patients supports further investigations on these rare tumors to deepen the importance of CTC isolation. Although it is not clear whether EpCAM expression might be originally present on tumor sarcoma cells or acquired during the mesenchymal-epithelial transition, the discovery of EpCAM on circulating sarcoma cells opens a new scenario in CTC detection in patients affected by a rare mesenchymal tumor.

1. Introduction

Sarcomas are relatively rare but particularly lethal tumors, with over 5,800 deaths per year in the United States [1], accounting for about 1% of all adult cancers and approximately 20% of pediatric solid malignancies [2]. The word sarcoma represents over fifty subtypes of soft tissue malignant tumors of mesenchymal origin. In 2013, the World Health Organization (WHO) Classification of Tumors of Soft Tissue and Bone has been published, according to the pathogenesis of soft tissue and bone tumors related to the histologic and genetic findings [3, 4].

The diagnosis is performed by hematoxylin and eosin staining of sections and immunohistochemistry. To date, radiographic imaging and PET are performed to detect recurrence and metastasis. However, different technologies are now available for molecular characterization of such tumor types, as recently discussed by Smith et al.; analyses as Polymerase Chain Reaction (PCR), fluorescent in situ hybridization (FISH), Real-Time PCR, and next-generation sequencing (NGS) or the presence of reciprocal chromosomal translocations and fusion genes may be useful for diagnosis and treatment of sarcoma patients [5].

Since most soft tissue sarcomas use the hematogenous dissemination to metastasize to lungs, liver, bones, and subcutaneous tissue whereas a small percentage may spread to lymph nodes [6, 7], it is possible to isolate and characterize circulating tumor cells (CTCs) from whole blood based on their biological and/or physical properties [8]. Furthermore, CTCs provide through their molecular evaluation an example of “liquid biopsy” useful for cancer patient care [9].

2. CTC

The definition of CTC is often associated with tumors of epithelial origin, even if this definition may include tumor cells derived from all solid tumors with both epithelial and mesenchymal origin. CTCs can be detected from the peripheral blood of cancer patients; ten years ago the prognostic significance of CTC isolated by CellSearch System among patients with metastatic breast [10–13], colorectal [14, 15], and prostate cancer [16, 17] has been demonstrated.

Circulating tumor cells referred to carcinomas were first described in 1869 by Ashworth [18] at autopsy examination, whereas Engell [19] described for the first time in 1955 the presence of cancer cells in the bloodstream. Every day a primary tumor releases an amount of CTCs of $10^6$ for gr of tumor; the majority of them die and only a small percentage, about 0.01%, survive, thus contributing to metastatic spread [20].
To date, the knowledge derived from years of studies focused on the role of CTCs comes from the analysis of epithelial tumors.

The physical and biological characteristics of CTCs have been employed for their enrichment and isolation; in particular, their larger size compared to blood cells and the presence, on their surface, of epithelial antigens allowed new assays for their isolation and characterization.

3. Carcinoma

The discovery of epithelial cell adhesion molecule (EpCAM) expression on epithelial cancer cells opened a new era in the development of several technologies for CTC enrichment and isolation. To date, due to the presence of new sensitive assays we can isolate at least single tumor cells between billions of peripheral blood cells. CellSearch is an EpCAM-based method, the only one approved by the Food and Drug Administration (FDA) for CTC enumeration. CellSearch assay was analytically validated by Allard et al. [21], and it is recognized as a very sensitive, accurate, and reproducible method [21]. The CellSearch kits used for epithelial CTC capture contain ferrofluids labeled with EpCAM, the staining reagents, 4,6-diamidino-2-phenylindole, dihydrochloride (DAPI), CD45-Allophycocyan (CD45-APC), and cytokeratin 8, 18, and 19 Phycerythrin (CK-PE) [22]. According to CellSearch manufacturer’s instructions, a CTC is characterized by positivity for EpCAM, cytokeratins (CKs), nuclear dye (DAPI), and negativity for CD45 [23], CTC enumeration, detected in 7.5 mL of blood, has prognostic value in metastatic colorectal cancer patients with a CTC value of 3 or fewer for 7.5 mL of blood. The presence and prognostic significance of CTC in blood of metastatic patients with small and non-small cell lung cancer [24, 25], stomach cancer [26], pancreatic cancer [27], ovarian cancer [28], and both advanced [29] and nonmuscle invasive bladder cancer [30, 31] have been also demonstrated.

In order to isolate CTC from cancer patients affected by carcinoma, studies have advanced from Reverse Transcriptase-Polymerase Chain Reaction- (RT-PCR-) based methods to immunomagnetic enrichment of tumor cells exploiting the presence of molecular markers as EpCAM on the CTC surface.

Immunomagnetic separation (IMS) may be achieved using Dynabeads, through enrichment or depletion of leukocytes with magnetic beads coated anti-CD45 antibody [32, 33]. For the enrichment beads coated with antibodies against specific antigens present on the cell surface, especially towards the human EpCAM or antibody against tumor specific markers can be used.

Among the molecular-based techniques developed, AdnaTest is a series of commercially available assays that combines an immunomagnetic enrichment of tumor cells followed by subsequent multiplex RT-PCR [34].

To date, microfluidic devices for CTC capture called CTC-Chip are also available; in recent years several devices have been created, both EpCAM and non-EpCAM-based, all able to provide living CTCs, suitable for molecular analysis and characterization [35–37].

A simple and versatile assay for CTC capture and genomic or proteomic analysis is ISET. Isolation by size of tumor cells (ISET) is a marker-independent assay for the isolation of intact CTCs from blood through direct filtration, using polycarbonate membrane with 8 μm diameter cylindrical pores taking advantage of the larger size of tumor cells compared with leukocytes. CTCs are then identified by cytromorphology and can be characterized by immunofluorescence (IF) assays but their enumeration is hard to be obtained [38, 39].

4. EMT

The epithelial-mesenchymal transition (EMT) has been widely investigated in carcinomas. Being characterized by loss of epithelial markers and acquisition of mesenchymal features, it allows carcinoma cells to escape from their structural confines, increasing their mobility and invasiveness, to enter into the bloodstream and to adhere and develop into distant metastases [40, 41]. Cells that undergo EMT are different from the conventional concept of CTCs: they express low or null EpCAM expression and might be missed by EpCAM-based approach [42–44]. Progression of solid tumors involves spatial and temporal occurrences of EMT, whereby tumor cells acquire a more invasive and metastatic phenotype. Subsequently, the disseminated mesenchymal tumor cells undergo the mesenchymal-to-epithelial transition (MET), at the site of metastases, which often recapitulate the pathology of their corresponding primary tumors. EMT is considered a reversible process of switch from an epithelial to a mesenchymal cellular phenotype. This transition leads to downregulation of epithelial markers as CKs and E-cadherin and to upregulation of mesenchymal biomarkers as vimentin, fibronectin, and N-cadherin [40, 45, 46]. EMT enhances migratory and invasive properties of cancer cells and their survival in the bloodstream. The following MET process is responsible for CTC extravasation and colonization in distant organs lesion which is expressed with metastatic disease [47–49].

5. Carcinosarcoma

Carcinosarcomas are rare biphenotypic tumors with characteristics of epithelial as well as sarcoma tumor cells [50, 51]. The hypothesis that stem/progenitor cells can play a role as common precursors for tumors of carcino/sarcoma phenotype such as squamomelanocytic tumors [52] and perhaps carcinosarcomas has been suggested.

Carcinosarcoma was originally described in 1972 by Dawson [53] and more recently studies on lung, ovarian, and uterine carcinosarcomas were performed. Paniz Mondolfi et al. [51] recently published a study performed on a primary cutaneous carcinosarcoma and demonstrated an immunoreactivity for EpCAM in both mesenchymal and epithelial components, suggesting that EpCAM might represent a potential target for cutaneous carcinosarcoma.
The presence, in carcinosarcoma tumors, of sarcomatous and epithelial tumor components led to further studies focused on the presence of epithelial markers on sarcoma cells.

6. Sarcoma

Few studies have been performed on sarcoma-derived CTCs, perhaps because sarcomas are considered relatively rare neoplasms despite their poor prognosis.

More recently, EpCAM-positive circulating cells were detected in soft tissue sarcoma patients and a genomic meta-analysis of gene expression profiles demonstrated that EpCAM mRNA is expressed in different sarcoma cell lines. Immunohistochemical staining revealed EpCAM protein expression in a subset of angiosarcomas and leiomyosarcomas and in all the osteosarcomas analyzed; in addition, a negative prognostic marker for leiomyosarcoma patients has been suggested [54].

The presence of EpCAM on CTC from metastatic sarcoma patients was shown by Vincenzi et al. using the CellSearch System. They enrolled twenty-three patients with metastatic STSs at first, second, and third line of chemotherapy and CTCs were detected in 43% of enrolled patients with a CTC count range of 0–4 cells/7.5 mL [8].

In a recent review by Chang et al. [55], CTC detection in sarcoma has been underlined; the majority of studies were performed on Ewing's sarcoma by RT-PCR analysis for the research of the fusion gene product associated with the disease EWS-FLI-1 and EWS-ERG marker. Data regarding the prognostic significance of CTC isolation in sarcoma, although poor, show a correlation between CTC presence and poor outcome or disease progression [56].

Cancer cells show a larger size compared to leukocytes and this physical characteristic was used to isolate and characterize CTC from sarcoma tumors for the first time by Chinen et al. [56]. In this study, which was performed on eleven patients with metastatic/recurrent or locally advanced soft tissue sarcomas, positivity for CTC detection has been shown for all patients enrolled, with a recovery rate of CTC from two to 48 per 8 mL of blood. For CTC characterization authors used anti-CD45 (specific marker for WBCs), anti-vimentin (mesenchymal-related marker), and anti-Pan CK (epithelial-related marker) antibodies, to discriminate CTCs from leukocytes in the immunochemistry assay.

Vimentin is considered the main protein associated with the EMT process and consequently with increased invasiveness, chemoresistance, and metastatic phenotype of these cells. The presence of vimentin on the surface of cancer cells is considered a sign of a mesenchymal phenotype of CTCs [57].

Although detection of cell-surface vimentin in cancer cells has been demonstrated in different studies [58, 59], its role as a biomarker by using a monoclonal antibody 84-1 for detecting CTC from blood of cancer patients affected by carcinoma as well as sarcoma has been established [57].

7. MET

If it is true that EMT has been suggested to promote the growth of epithelial tumor cells at distant sites during metastasis, the inverse process MET might be considered as an efficient process for the dissemination of sarcoma cells.

Several types of sarcomas, including synovial sarcoma, leiomyosarcoma, chondrosarcoma, osteosarcoma, chordoma, epithelioid sarcoma, and ES/PNET, have been reported to show epithelial differentiation on the basis of detection of epithelial markers including E-cadherin. Recent findings reveal that mesenchymal-epithelial transition may exist in sarcomas, leading to a switch towards an epithelial phenotype. Accumulating evidences suggest that deeper investigation and understanding of MET in sarcomas would shed light on the pathogenesis of sarcomas and might lead to identification of potential clinical biomarkers for prognosis and targets for sarcoma therapeutics.

In this view, EMT/MET processes may be considered the link between carcinoma and sarcoma tumors, two distinct and reversible regulated mechanisms employed by tumor cells, both responsible for developing distant metastases.

8. Discussion and Conclusion

Although it is not clear whether tumor sarcoma cells constitutively express EpCAM or alternatively they acquire it during the mesenchymal-epithelial transition, the discovery of EpCAM on circulating sarcoma cells opens a new scenario in CTC detection in patients affected by rare tumors.

CellSearch System offers the possibility to study the expression of an additional marker of interest by the use of the fourth channel. To date, this channel has been used to study the apoptotic status of CTCs integrating the system with a monoclonal antibody, anti-M30 [60], anti Bcl-2 [61], and anti-M65 [62].

CellSearch, an EpCAM-based assay, can be integrated with an anti-vimentin antibody in its fourth channel, to discriminate sarcoma circulating cells positive for EpCAM and vimentin and negative for CD45, from leucocytes positive for CD45.

Vimentin is considered a specific marker of mesenchymal derivation or differentiation and its expression in sarcoma circulating cells, presumably undergoing MET, seems contradictory and requires further studies.

Satelli et al. [63] developed an anti-vimentin antibody able to discriminate the expression of cell-surface vimentin, mainly associated with cancer cells, from the intracellular vimentin expressed by most white blood cells in order to exclude bias to use this protein as a CTC marker.

Using the CellSearch System this bias could be excluded: the choice of intracellular or extracellular antibody is indifferent because we may discriminate the false positive results by the leucocytes positivity for CD45.

More than ten years ago, CTC enumeration was validated as prognostic biomarker in metastatic breast cancer using the US Food and Drug Administration- (FDA-) cleared system CellSearch (Jansen Diagnostics, LLC, Raritan, NJ, USA); we believe that studies on biomarkers in sarcoma patients may quickly evolve in the next future through CTC enumeration as well as phenotypic and genotypic characterization.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

References
[1] R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics,” CA—A Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012.
[2] E. K. Amankwah, A. P. Conley, and D. R. Reed, “Epidemiology and therapies for metastatic sarcoma,” Clinical Epidemiology, vol. 5, no. 1, pp. 147–162, 2013.
[3] C. D. Fletcher, P. Hogendoorn, F. Mertens, and J. Bridge, WHO Classification of Tumours of Soft Tissue and Bone, IARC Press, Lyon, France, 4th edition, 2013.
[4] L. A. Doyle, “Sarcoma classification: an update based on the 2013 world health organization classification of tumors of soft tissue and bone,” Cancer, vol. 120, no. 12, pp. 1763–1774, 2014.
[5] S. M. Smith, J. Coleman, J. A. Bridge, and O. H. Iwenofu, “Molecular diagnostics in soft tissue sarcomas and gastrointestinal stromal tumors,” Journal of Surgical Oncology, vol. 111, no. 5, pp. 520–531, 2015.
[6] E. Pennacchioli, G. Tosti, M. Barberis et al., “Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?” Clinical and Experimental Metastasis, vol. 29, no. 7, pp. 757–773, 2012.
[7] A. Gronchi, S. Lo Vullo, C. Colombo et al., “Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival,” Annals of Surgery, vol. 251, no. 3, pp. 506–511, 2010.
[8] B. Vincenzi, E. Rossi, A. Zoccoli et al., “Circulating tumour cell in soft tissue sarcomas patients,” Annals of Oncology, vol. 23, p. 489, 2012.
[9] K. Pantel and C. Alix-Panabières, "Real-time liquid biopsy in cancer patients: fact or fiction?" Cancer Research, vol. 73, no. 21, pp. 6384–6388, 2013.
[10] M. Cristofanilli, G. T. Budd, M. J. Ellis et al., “Circulating tumor cells, disease progression, and survival in metastatic breast cancer,” The New England Journal of Medicine, vol. 351, no. 8, pp. 781–791, 2004.
[11] M. Cristofanilli, D. F. Hayes, G. T. Budd et al., “Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer,” Journal of Clinical Oncology, vol. 23, no. 7, pp. 1420–1430, 2005.
[12] G. T. Budd, M. Cristofanilli, M. J. Ellis et al., “Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer,” Clinical Cancer Research, vol. 12, no. 21, pp. 6403–6409, 2006.
[13] D. F. Hayes, M. Cristofanilli, G. T. Budd et al., “Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival,” Clinical Cancer Research, vol. 12, no. 14, part 1, pp. 4218–4224, 2006.
[14] S. J. Cohen, C. J. Punt, N. Iannotti et al., “Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 19, pp. 3213–3221, 2008.
[15] S. J. Cohen, C. J. A. Punt, N. Iannotti et al., “Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer,” Annals of Oncology, vol. 20, no. 7, pp. 1223–1229, 2009.
[16] J. S. De Bono, H. I. Scher, R. B. Montgomery et al., “Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer,” Clinical Cancer Research, vol. 14, no. 19, pp. 6302–6309, 2008.
[17] H. I. Scher, X. Jia, J. S. de Bono et al., “Circulating tumor cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data,” The Lancet Oncology, vol. 10, no. 3, pp. 233–239, 2009.
[18] T. R. Ashworth, “A case of cancer in which cells similar to those in the tumours were seen in the blood after death,” Australian Medical Journal, vol. 14, pp. 146–147, 1869.
[19] H. C. Engell, “Cancer cells in the circulating blood; a clinical study on the occurrence of cancer cells in the peripheral blood and in venous blood draining the tumour area at operation,” Acta chirurgica Scandinavica. Supplementum, vol. 201, pp. 1–70, 1955.
[20] X. Zhe, M. L. Cher, and R. D. Bonfil, “Circulating tumor cells: finding the needle in the haystack,” American Journal of Cancer Research, vol. 1, no. 6, pp. 740–751, 2011.
[21] W. J. Allard, J. Matera, M. C. Miller et al., “Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases,” Clinical Cancer Research, vol. 10, no. 20, pp. 6897–6904, 2004.
[22] Food and Drug Administration, “510 (k) Substantial equivalence determination decision,” http://www.accessdata.fda.gov/cdrh_docs/reviews/K042259.pdf.
[23] http://documents.cellsearchctc.com/pdf/e631600001/e631600001_EN.pdf.
[24] M. G. Krebs, J.-M. Hou, R. Sloane et al., “Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches,” Journal of Thoracic Oncology, vol. 7, no. 2, pp. 306–315, 2012.
[25] T. J. N. Hiltermann, M. M. Poe, A. van den Berg et al., “Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor,” Annals of Oncology, vol. 23, no. 11, Article ID mds138, pp. 2937–2942, 2012.
[26] K. Hiraiwa, H. Takeuchi, H. Hasegawa et al., “Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers,” Annals of Surgical Oncology, vol. 15, no. 11, pp. 3092–3100, 2008.
[27] T. Kurihara, T. Itoi, A. Sofuni et al., “Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result,” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 15, no. 2, pp. 189–195, 2008.
[28] A. Poveda, S. B. Kaye, R. McCormack et al., “Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer,” Gynecologic Oncology, vol. 122, no. 3, pp. 567–572, 2011.
[29] M. Rink, F. K. H. Chun, S. Minner et al., “Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer,” BJU International, vol. 107, no. 10, pp. 1668–1675, 2011.
[30] P. Gazzaniga, A. Gradilone, E. de berardinis et al., “Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis,” Annals of Oncology, vol. 23, no. 9, pp. 2352–2356, 2012.
[31] P. Gazzaniga, E. de Berardinis, C. Raimondi et al., “Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer,” International Journal of Cancer, vol. 135, no. 8, pp. 1978–1982, 2014.
[32] L. Yang, J. C. Lang, P. Balasubramanian et al., “Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells,” Biotechnology and Bioengineering, vol. 102, no. 2, pp. 521–534, 2009.

[33] K. Shibata, M. Mori, S. Kitano, and T. Akiyoshi, “Detection of ras gene mutations in peripheral blood of carcinoma patients using CD45 immunomagnetic separation and nested mutant allele specific amplification,” International Journal of Oncology, vol. 12, no. 6, pp. 1333–1338, 1998.

[34] T. Todenhöfer, J. Hennenlotter, S. Feyerabend et al., “Pre-enrichment enrichment process for circulating tumor cells from the prostate cancer patients,” Anticancer Research, vol. 32, no. 8, pp. 3507–3513, 2012.

[35] S. Nagraath, L. V. Sequist, S. Maheswaran et al., “Isolation of rare circulating tumour cells in cancer patients by microchip technology,” Nature, vol. 450, no. 7173, pp. 1235–1239, 2007.

[36] S. L. Stott, C. H. Hsu, D. I. Tsukrov et al., “Isolation of circulating tumor cells using a microvortex–generating herringbone-chip,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 43, pp. 18392–18397, 2010.

[37] W. Harb, A. Fan, T. Tran et al., “Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay,” Translational Oncology, vol. 6, no. 5, pp. 528–538, 2013.

[38] G. Vona, A. Sabile, M. Louha et al., “Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells,” American Journal of Pathology, vol. 156, no. 1, pp. 57–63, 2000.

[39] S. Zheng, H. Lin, J.-Q. Liu et al., “Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells,” Journal of Chromatography A, vol. 1162, no. 2, pp. 154–161, 2007.

[40] J. P. Thierry, “Epithelial–mesenchymal transitions in tumour progression,” Nature Reviews Cancer, vol. 2, no. 6, pp. 442–454, 2002.

[41] P. S. Steeg, “Metastasis suppressors alter the signal transduction of cancer cells,” Nature Reviews Cancer, vol. 3, no. 1, pp. 55–63, 2003.

[42] T. M. Gorges, I. Tinhofer, M. Drosch et al., “Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition,” BMC Cancer, vol. 12, article 178, 2012.

[43] E. A. Punnoose, S. K. Atwal, J. M. Spoerke et al., “Molecular biomarker analyses using circulating tumor cells,” PLoS ONE, vol. 5, no. 9, Article ID e12517, pp. 1–12, 2010.

[44] R. Königsberg, E. Obermayr, G. Bises et al., “Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients,” Acta Oncologica, vol. 50, no. 5, pp. 700–710, 2011.

[45] J. Yang and R. A. Weinberg, “Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis,” Developmental Cell, vol. 14, no. 6, pp. 818–829, 2008.

[46] K. Polyak and R. A. Weinberg, “Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits,” Nature Reviews Cancer, vol. 9, no. 4, pp. 265–273, 2009.

[47] H. Hugo, M. L. Ackland, T. Blick et al., “Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression,” Journal of Cellular Physiology, vol. 213, no. 2, pp. 374–383, 2007.

[48] A. J. Armstrong, M. S. Marengo, S. Oltean et al., “Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers,” Molecular Cancer Research, vol. 9, no. 8, pp. 997–1007, 2011.

[49] S. Oltean and D. O. Bates, “Hallmarks of alternative splicing in cancer,” Oncogene, vol. 33, no. 46, pp. 5311–5318, 2014.

[50] B. Choijams, S. Jimi, T. Kondo et al., “CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor),” Stem Cells, vol. 29, no. 10, pp. 1485–1495, 2011.

[51] A. E. Paniz Mondolfi, G. Jour, M. Johnson et al., “Primary cutaneous carcinosarcoma: insights into its clonal origin and mutational pattern expression analysis through next-generation sequencing,” Human Pathology, vol. 44, no. 12, pp. 2853–2860, 2013.

[52] G. Jour, A. Paniz Mondolfi, J. Reidy et al., “Squamous-melanocytic tumor: a case report and further insights into its possible histogenesis,” The American Journal of Dermatopathology, vol. 36, no. 6, pp. 517–521, 2014.

[53] E. K. Dawson, “Carcino-sarcoma of the skin,” Journal of the Royal College of Surgeons of Edinburgh, vol. 17, no. 4, pp. 243–246, 1972.

[54] K. Ward, C. Amaya, K. Verma et al., “Epithelial cell adhesion molecule is expressed in a subset of sarcomas and correlates to the degree of cytological atypia in leiomyosarcomas,” Molecular and Clinical Oncology, vol. 3, no. 1, pp. 31–36, 2015.

[55] L. Chang, G. Asatryan, S. M. Dry, and A. W. James, “Circulating tumor cells in sarcomas: a brief review,” Medical Oncology, vol. 32, no. 1, article 430, 2015.

[56] L. T. Chinen, C. A. Mello, E. A. Abdallah et al., “Isolation, detection, and immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarcoma using isolation by size of tumor cells: a window on sarcoma-cell invasion,” OncoTargets and Therapy, vol. 7, pp. 1609–1617, 2014.

[57] A. Satelli and S. Li, “Vimentin in cancer and its potential as a molecular target for cancer therapy,” Cellular and Molecular Life Sciences, vol. 68, no. 18, pp. 3033–3046, 2011.

[58] M. E. Kidd, D. K. Shumaker, and K. M. Ridge, “The role of vimentin intermediate filaments in the progression of lung cancer,” American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 1, pp. 1–6, 2014.

[59] A. Smith, T. N. Teknos, and Q. Pan, “Epithelial to mesenchymal transition in head and neck squamous cell carcinoma,” Oral Oncology, vol. 49, no. 4, pp. 287–292, 2013.

[60] E. Rossi, U. Basso, R. Celadini et al., “M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis,” Clinical Cancer Research, vol. 16, no. 21, pp. 5233–5243, 2010.

[61] J. B. Smerage, G. T. Budd, G. V. Doyle et al., “Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer,” Molecular Oncology, vol. 7, no. 3, pp. 680–692, 2013.

[62] J.-M. Hou, A. Greystoke, L. Lancashire et al., “Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy,” The American Journal of Pathology, vol. 175, no. 2, pp. 808–816, 2009.

[63] A. Satelli, Z. Brownlee, A. Mitra, Q. H. Meng, and S. Li, “Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response,” Clinical Chemistry, vol. 61, no. 1, pp. 259–266, 2014.